Women’s healthcare market (contraception, infertility, and women’s disease-related
fields) expanding at an average annual rate of approximately 3.3%* Growth Area with Significant Unmet Needs
Source: Fuji Keizai Co., Ltd. “Latest Trends and Future
Outlook of the Contraception, Infertility, and Women’s Disease-Related Market” Unauthorized reproduction
prohibited. *CAGR: approximately 3.3% (2024: ¥128.6 billion – 2035 forecast: ¥184.1 billion)
Our Strengths
Our Group’s Competitive Strengths
Why ASKA Is
the Partner of Choice in This Growth Area
Deep Expertise in the Hormone Field
More than 100 years of specialized experience in the hormone field
One of the leading
market positions in Japan in the obstetrics & gynecology and thyroid fields
Long-Established R&D Platform
An integrated R&D structure covering the entire process from basic research to
commercialization
Continuous pipeline creation through a combination of in-house drug
discovery and strategic licensing/acquisition
Stable Revenue Model
A diversified revenue structure supported by multiple products and businesses, without dependence on
any single product
A business model focused on specialty areas, making it less susceptible
to drug price revisions and changes in market conditions
Growth Strategy
Growth Strategy
Strengthening existing businesses while expanding into new areas — from Japan
to the global market
Five Pillars Driving Growth
Domestic Pharmaceutical
Addressing sexual health challenges and leading the way toward a healthier society.
Drug Discovery
Advancing the launch of in-house developed products, pipeline expansion, and overseas out-licensing
through ASKA’s unique drug discovery platform.
Global
Creating value in specialty fields and strengthening our presence in global markets, primarily in
Asia.
Animal Health
Contributing to the realization of sustainable animal health through unique products and
solutions.
Testing and Around-the-Pill
Contributing to total healthcare through prevention, testing/diagnosis, treatment, and prognosis
management utilizing diagnostics and medical devices.
Roadmap to 2035 Targets
Milestones
Net Sales
¥71.1billion
Operating Margin
8.2%
FY2025
Mid-Term Management Plan2028
FY2026-2028
Net Sales
¥85.0billion
Operating Margin
10%
FY2028
Deepening core strengths for sustainable growth and building a business foundation to
support global expansion
Mid-Term Management Plan2031
FY2029-2031
Net Sales
¥100.0billion
Operating Margin
12%
FY2031
Expanding into new disease areas and establishing a foundation for global expansion
Mid-Term Management Plan2035
FY2032-2035
Net Sales
¥150.0billion
Operating Margin
15%
FY2035
Establishing a strong presence in global markets through the integration of in-house
developed products and group synergies
Toward 2035 Targets
Roadmap
Mid-Term Management Plan2028
FY2026-2028
Mid-Term Management Plan2031
FY2029-2031
Mid-Term Management Plan2035
FY2032-2035
Domestic Pharmaceuticals
Aim for further growth as a leading company in women's health
Enter into new
therapeutic areas
In addition to women's health, tackle men's health-related diseases
Raise our
presence in new therapeutic areas
Become a leading company in solving health issues specific to women and to men
Drug Discovery
Construct a drug discovery platform that forms a unique strength in the field of
gynecology
Aim to be a specialty pharma company in the field of gynecology and promote
collaboration and partnerships with pharmaceutical companies in Japan and overseas
Build the foundation for early-stage out-licensing of drug discovery seeds
Make progress in expanding market launches, pipeline, and overseas out-licensing
for in-house discovered compounds
Global
Build a business foundation for Hataphar and MedChoice
Expand operations at
Hataphar's new factory and its product lineup
Raise our presence as a specialty pharma company in Southeast Asia, primarily in
Vietnam and the Philippines
Demonstrate a global presence in specialty areas
Animal Health
Expand the market for companion animal and livestock products
Tackle new
challenges to expand distribution channels
Aim to be an industry-leading company in the field of endocrinology
Develop
overseas markets, primarily in Asia
Achieve greater livestock production efficiency and pet well-being through
competitive and unique products and solutions
Testing and Around-the-Pill
Promote collaboration with business partners, centered on business utilizing trace
analysis technologies
Enhance testing related to sex and aging
Create new value through collaboration between our proprietary technologies and
business partners
Contribute to the achievement of a healthy and sustainable society through
innovative testing, medical devices, etc
ありたい姿
2035
Aspiring Vision
Aspiring Vision 2035
Purpose
We will realize a healthy tomorrow and
future for all lives
Vision
Toward a Specialty Healthcare Company Based in Japan, Pioneering the Future Globally